NASDAQ$AXGN

Axogen Inc. · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Axogen reported first quarter results with revenue increase and bottom line improvement.

Axogen, Inc. reported a 12.9% increase in first-quarter revenue, reaching $41.4 million compared to the previous year. The company's gross margin improved to 78.8%, and it reduced its net loss to $6.6 million, or $0.15 per share. The company is focused on higher productivity to reach profitability and positive cashflow.

  • First quarter revenue increased by 12.9% year-over-year, reaching $41.4 million.
  • Gross margin improved to 78.8% compared to 77.7% in the same quarter of the previous year.
  • Net loss decreased to $6.6 million, or $0.15 per share, from $7.1 million, or $0.17 per share, year-over-year.
  • Adjusted EBITDA was $1.0 million, compared to an adjusted EBITDA loss of $3.8 million in the first quarter of 2023.

Headline financials

Total Revenue

$41.4M

Previous: $36.7M+12.9%
EPS

-$0.15

Previous: -$0.10-50.0%
Gross Margin

78.8%

Previous: 81.7%-3.5%
Adjusted EBITDA

$1M

No prior period
Total Cash and Restricted Cash

$21.7M

No prior period
Capital Expenditures

-$924K

Previous: -$4.3M+78.5%
Free Cash Flow

-$7.56M

Previous: -$11.4M+33.6%
Net Income

-$6.64M

Previous: -$7.07M+6.2%
Operating Income

-$4.56M

Previous: -$7.34M+37.9%
Gross Profit

$32.6M

Previous: $30M+8.9%
Cash & Equivalents

$15.7M

Previous: $7.71M+103.9%
Total Assets

$187M

Previous: $189M-1.6%
R&D Expense

$7.41M

No prior period
Stock-Based Comp

$3.92M

Previous: $2.95M+32.7%

Revenue & EPS history

Axogen · Revenue · Quarterly

$41.4M

Q1 2024+12.9%vs Q1 2023
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Forward guidance

Axogen maintains its annual revenue guidance in the range of $177 million to $181 million, representing approximately 11% to 14% growth. Gross margin is expected to be in the range of 76% to 79% for the full year. The company anticipates being net cashflow positive cumulatively for the period from April 1st through year end.

Tailwinds

  • Annual revenue guidance maintained between $177 million and $181 million.
  • Projected revenue growth rate of approximately 11% to 14%.
  • Gross margin guidance reiterated in the range of 76% to 79%.
  • Expect to be net cashflow positive cumulatively from April 1st through year end.
  • Focus on higher productivity as revenue grows.

Headwinds

  • Global supply chain issues.
  • Hospital staffing issues.
  • Product development challenges.
  • Regulatory process and approvals.
  • Global business disruption caused by Russia’s invasion of Ukraine and related sanctions, recent geopolitical conflicts in the Middle East, potential disruptions due to management transitions

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+1.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+6.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+39.1%

Q2 2024

Best reaction

-27.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+9.9%+2.6%
Q4 2025-6.6%-10.3%-8.8%
Q3 2025+22.8%+28.6%+58.5%
Q1 2025-23.2%-33.6%-33.4%
Q4 2024+11.7%+11.1%+5.4%
Q3 2024-17.4%-13.4%-2.7%
Q2 2024+39.1%+42.2%+64.4%
Q1 2024-11.7%-11.1%+4.1%
Q4 2023-14.4%-17.4%-26.7%
Q3 2023+37.4%+27.7%+88.8%
Q2 2023-20.8%-27.9%-27.0%
Q1 2023-1.8%-4.6%-0.8%
Q4 2022+11.6%+9.2%+37.8%
Q3 2022+19.0%+21.4%+0.6%
Q2 2022+2.1%+1.2%-10.7%
Q1 2022+23.4%+17.7%+16.8%
Q4 2021+8.0%+27.1%+6.2%
Q3 2021-13.3%-6.0%-37.3%
Q2 2021-2.5%-9.5%-12.5%
Q1 2021+14.9%+13.3%-1.2%
Q4 2020+3.6%+7.0%-7.7%
Q3 2020+3.4%+10.4%+18.0%
Q2 2020+0.3%-2.3%-1.7%
Q1 2020-14.7%-9.6%+10.9%
Q4 2019-17.6%-15.8%-36.3%
Q3 2019+12.4%+13.3%+23.8%
Q2 2019-27.3%-21.8%-5.5%
Q1 2019-2.1%-5.4%-15.7%
Q4 2018+1.6%+6.7%+13.4%
Q3 2018+9.3%+12.8%-1.3%
Q2 2018-12.6%-13.1%-2.4%
Q1 2018-5.1%+5.2%+14.2%
Q4 2017+8.8%+4.5%+17.0%
Q3 2017+10.7%+15.3%+28.5%
Q2 2017-4.8%-6.4%+14.7%
Q1 2017+3.3%+3.7%+25.6%
Q4 2016-0.5%-0.5%-5.2%
Q3 2016-1.7%-10.9%-7.4%
Q2 2016+25.1%+26.2%+32.9%
Q1 2016-0.4%
Q4 2015-4.7%
Q3 2015+17.3%
Q2 2015+5.4%
Q1 2015+3.1%
Q4 2014+3.8%
Q3 2014+5.5%
Q2 2014+1.3%
Q1 2014+1.6%
Q4 2013-8.5%
Q3 2013+1.8%
Q2 2013-0.3%
Q1 2013-14.7%
Q4 2012+4.5%
Q3 2012-1.8%
Q2 2012+18.2%
Q1 2012+0.3%
Q4 2011-4.5%
Q3 2011-14.8%
Q2 2010+0.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010-6.8%
Q3 2010+9.7%
Q1 2010-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro